Therefore, the evaluation of MMPs circulating levels, and in particular the use of OPN and MMP-9 as circulating biomarkers, may improve the current diagnostic strategies for melanoma and predict the aggressiveness of tumors, in order to personalize the therapeutic approach for the patients. The gene discussed is MMP9; the disease is melanoma.